WallStreetZenWallStreetZen

NASDAQ: CAPR
Capricor Therapeutics Inc Stock

$5.55+0.14 (+2.59%)
Updated Jun 11, 2024
CAPR Price
$5.55
Fair Value Price
N/A
Market Cap
$176.55M
52 Week Low
$2.68
52 Week High
$8.22
P/E
-6.69x
P/B
9.58x
P/S
7.86x
PEG
N/A
Dividend Yield
N/A
Revenue
$27.10M
Earnings
-$24.31M
Gross Margin
100%
Operating Margin
-89.72%
Profit Margin
-89.7%
Debt to Equity
1.68
Operating Cash Flow
-$31M
Beta
1.21
Next Earnings
Aug 5, 2024
Ex-Dividend
N/A
Next Dividend
N/A

CAPR Overview

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CAPR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CAPR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CAPR is poor value based on its book value relative to its share price (9.58x), compared to the US Biotechnology industry average (6.25x)
P/B vs Industry Valuation
CAPR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CAPR due diligence checks available for Premium users.

Be the first to know about important CAPR news, forecast changes, insider trades & much more!

CAPR News

Valuation

CAPR price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-6.69x
Industry
-3.83x
Market
29.53x

CAPR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
9.58x
Industry
6.25x
CAPR is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CAPR's financial health

Profit margin

Revenue
$4.9M
Net Income
-$9.8M
Profit Margin
-199.6%
CAPR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CAPR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$49.4M
Liabilities
$31.0M
Debt to equity
1.68
CAPR's short-term assets ($41.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CAPR's short-term assets ($41.41M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CAPR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CAPR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$1.3M
Investing
-$9.5M
Financing
$2.3M
CAPR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CAPR vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CAPR$176.55M+2.59%-6.69x9.58x
XFOR$176.33M+0.96%-1.52x170.21x
CRBU$175.22M+3.19%-1.33x0.51x
CLLS$178.09M-3.50%-2.23x1.97x
OTLK$178.59M+7.92%-0.67x-1.33x

Capricor Therapeutics Stock FAQ

What is Capricor Therapeutics's quote symbol?

(NASDAQ: CAPR) Capricor Therapeutics trades on the NASDAQ under the ticker symbol CAPR. Capricor Therapeutics stock quotes can also be displayed as NASDAQ: CAPR.

If you're new to stock investing, here's how to buy Capricor Therapeutics stock.

What is the 52 week high and low for Capricor Therapeutics (NASDAQ: CAPR)?

(NASDAQ: CAPR) Capricor Therapeutics's 52-week high was $8.22, and its 52-week low was $2.68. It is currently -32.49% from its 52-week high and 107.09% from its 52-week low.

How much is Capricor Therapeutics stock worth today?

(NASDAQ: CAPR) Capricor Therapeutics currently has 31,811,470 outstanding shares. With Capricor Therapeutics stock trading at $5.55 per share, the total value of Capricor Therapeutics stock (market capitalization) is $176.55M.

Capricor Therapeutics stock was originally listed at a price of $450.00 in Feb 13, 2007. If you had invested in Capricor Therapeutics stock at $450.00, your return over the last 17 years would have been -98.77%, for an annualized return of -22.78% (not including any dividends or dividend reinvestments).

How much is Capricor Therapeutics's stock price per share?

(NASDAQ: CAPR) Capricor Therapeutics stock price per share is $5.55 today (as of Jun 11, 2024).

What is Capricor Therapeutics's Market Cap?

(NASDAQ: CAPR) Capricor Therapeutics's market cap is $176.55M, as of Jun 13, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Capricor Therapeutics's market cap is calculated by multiplying CAPR's current stock price of $5.55 by CAPR's total outstanding shares of 31,811,470.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.